- Display 15 Products per page
Out-of-Pocket Healthcare Expenditures in the United States
Published: April 17, 2017 | Price: $796.00 – $1,592.00
Out-of-Pocket Healthcare Expenditures in the United States Out-of-Pocket Healthcare Expenditures in the United States examines the average person’s out-of-pocket medical costs, including: Distribution of Out-of-Pocket Spending for the Average Person, 2016, 2021 Consumer Out-of-Pocket Expenditures per Worker, 2011–2021 Consumer Out-of-Pocket Expenditures by Type, 2011–2021 Proportion of Consumer Out-of-Pocket Spending by Type of Healthcare Expenditure, 2011, 2016, 2021 Average Share Paid Out-of-Pocket by U.S. Residents with Healthcare Spending by Percentile of Total Health Spending and Type of Service, 2016 Average Share...
World Sleep Apnea Devices Market
Published: February 19, 2017 | Price: $796.00 – $1,592.00
World Sleep Apnea Device Markets is Kalorama Information's authoritative study on this high-growth market. As part of its coverage, the report provides the following data: Worldwide Respiratory Sleep Apnea APAP Market, 2014-2021 ($millions) Sleep Apnea Bi-Level Market Worldwide Respiratory Sleep Apnea Bi-Level Market, 2014-2021 ($millions Sleep Apnea Facial Interface and Diagnostic Device Market Worldwide Respiratory Sleep Apnea Facial Interface and Diagnostic Device Market, 2014-2021 ($millions) Prevalence of Sleep Apnea, 2015 Sleep Apnea Prevalence by Region and Country, 2015 Worldwide...
Retail Clinics: Customer Survey 2018
Published: June 22, 2018 | Price: $800.00 – $1,600.00
Are Consumers Visiting Retail Clinics? What For? How Satisfied are Retail Clinic Customers? These questions and many others are answered in this report from Kalorama Information. Kalorama has covered the market for clinics located within a retail health setting since 2007, and has recently concluded a web-based survey of 2000 U.S. adults, where hundreds of retail clinic users were interviewed. This report provides the results of this survey. Questions Asked Include: Have You Ever Visited A Retail Clinic? Gender Of...
Inhaled Insulin: A Market Briefing
Published: July 1, 2004 | Price: $895.00 – $1,790.00
Alternative routes of administration for insulin has been one of the leading drivers of drug delivery industry. Although transdermal and transmucosal systems have shown promise and true oral delivery remains a goal, pulmonary delivery has emerged as the leading area of development. Several major players in the pharmaceutical industry have given their backing to inhaled insulin projects, and product launches are imminent. However, the exact make-up of the market, patient acceptance, and regulatory progress are still not completely clear. This...
Ambulatory Infusion Pumps in Pain Management: A Market Briefing
Published: August 1, 2004 | Price: $895.00 – $1,790.00
After years of neglect, concerns over pain, how it is assessed and managed on a patient-by-patient basis have captured the attention of health care professionals and the public. There are a variety of issues that have acted to draw this attention, including the high prevalence of pain, continuing evidence that pain is undertreated and a growing awareness of the negative consequences of poor pain management. Infusion pumps were first introduced in the 1960s. These devices ushered in a whole new...
Molecular Nanotechnology in Medicine: A Market Briefing
Published: September 1, 2004 | Price: $895.00 – $1,790.00
Nanotechnology is no longer a bench-top curiosity. It is becoming a real commercial force for a variety of applications. This market briefing discusses the state of play in the race to commercialize products and forecasts likely market scenarios. The briefing forecasts the market in generally promising areas such as cancer therapeutics, specialized drug delivery, diagnostics, and topical therapies, reviewing what companies are doing in those markets.
New Anticoagulant Therapies: A Market Briefing
Published: October 1, 2004 | Price: $895.00 – $1,790.00
There is a pressing need for new anticoagulant therapeutics in human medicine. To meet this need, developers are reformulating traditional cornerstone therapeutics such as heparin and looking to new classes such as DTIs to prevent stroke and myocardial infarction and treat deep vein thrombosis and a host of other emerging indications. This briefing analyzes the potential world medical markets for new anticoagulant therapies. Revenue projections through 2010 are made for four geographic regions and for two potentially blockbuster products. This...
U.S. Market for Clinical Information Systems – An Analysis of the Growing Use of Information Technology for Hospital-Based Patient Care, The
Published: October 1, 2005 | Price: $895.00 – $5,990.00
Information technology (IT) has the potential to improve the quality, safety and efficiency of clinical care. IT is not new to the hospital setting. Computers and software have been used for many years to improve the paper-based administrative functions of hospital support staff, such as scheduling and billing. But the use of IT in the clinical setting to optimize, streamline and simplify patient records, testing, imaging and operating room procedures has lagged behind its medical administrative applications. The evolution of...
Congestive Heart Failure – Major World Markets, Volume I – Pharmaceutical Management
Published: February 1, 2008 | Price: $895.00 – $6,990.00
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment. Kalorama Information's Congestive Heart Failure, Major...
Successful Commercialization Strategies for New Healthcare Products and Technologies
Published: June 1, 2003 | Price: $995.00 – $2,992.00
According to the Pharmaceutical Research and Manufacturers of America (PhRMA) more than 1,000 drugs are in various stages of development. Similarly, breakthroughs in the medical device arena such as coronary stents, implantable defibrillators, and minimally invasive bypass surgery and advances in DNA-based tests and other advanced diagnostics are detecting cancer and other diseases earlier when they are more treatable are moving from dream to reality. It is obvious that even if all of these drugs and devices make it to...
Molecular Diagnostics for Blood Banking Applications: Testing volume, cost per test, and market potential
Published: August 1, 2004 | Price: $995.00 – $1,910.00
Blood banking has been the most dynamic testing segment to adopt molecular diagnostics approaches since their introduction. Screening for HIV, HCV and HBV in donated blood, plasma and organs has largely been done by immunoassay procedures. In conjunction with background screening, this has become a very effective approach toward guaranteeing the safety of the blood/organ supply. However, there is a lag time between infection with these viruses and the production of antibodies against them. In some cases, such as HBV,...
Molecular Diagnostics for Pharmacogenetic Testing: Testing volume, cost per test, and market potential
Published: October 1, 2004 | Price: $995.00 – $1,990.00
The field of pharmacogenetics promises to open up new opportunities for the diagnostic industry at the same time it opens the door to more effective therapeutics. Pharmacogenetics is based on the principle that the effects of a given medication when administered to a patient are determined, at least in part, by his or her genetic constitution. Differences in drug metabolism may lead to varying adverse events or more pronounced adverse events in different individuals, and differing metabolism may also lead...
Molecular Diagnostics for Infectious Disease Testing: Testing volume, cost per test, and market potential
Published: October 1, 2004 | Price: $995.00 – $1,990.00
Currently, the largest market application segment for molecular diagnostics is that for infectious disease testing. The segment is expected to grow at an annual rate between 7% and 8% over the next few years will present some excellent market opportunites for molecular diagnostic competitors. This summary report, extracted from Kalorama Information’s U.S. Market for Molecular Diagnostics, (2nd Edition, May 2004), focuses on the technologies and application of molecular diagnostics in the field of infectious disease testing. The major market effects...
Molecular Diagnostics for Inherited Disease Testing: Testing volume, cost per test, and market potential
Published: October 1, 2004 | Price: $995.00 – $1,990.00
Gene and chromosome testing for inherited diseases currently represents the third largest molecular diagnostics testing segment in the U.S. Assays in this market address applications in genetic carrier and predisposition testing. Currently, most testing is for prenatal screening and for assessing clinically suspect newborns for various chromosomal abnormalities (e.g., Down’s syndrome, fragile X syndrome). Some testing is used for genetic counseling for couples planning to have children. Such diagnostics test for the presence of carrier states of diseases such as...
Autism Therapeutics: A Market Briefing
Published: January 15, 2005 | Price: $995.00 – $1,990.00
Despite the traditional notion that nothing therapeutic can be accomplished for the 1.5 million Americans with autism and the 2 million more throughout the world, there are pharmacologic approaches to the disease that are providing some help for patients and garnering revenues for drug companies. This Market Briefing reviews the market for drugs used in the treatment of autism and related disorers, including Antidepressants, Anti-Anxiety drugs, Anti-psychotics, Anti-convulsants, and CNS stimulants for ADHD-related symptoms, forecasting revenues through 2009 gloabally and...